Form 8-K - Current report:
SEC Accession No. 0001104659-24-115911
Filing Date
2024-11-08
Accepted
2024-11-08 16:36:40
Documents
15
Period of Report
2024-11-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2427608d2_8k.htm   iXBRL 8-K 34569
2 EXHIBIT 5.1 tm2427608d2_ex5-1.htm EX-5.1 6588
3 EXHIBIT 10.1 tm2427608d2_ex10-1.htm EX-10.1 218228
  Complete submission text file 0001104659-24-115911.txt   490791

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apre-20241108.xsd EX-101.SCH 3006
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apre-20241108_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apre-20241108_pre.xml EX-101.PRE 22353
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2427608d2_8k_htm.xml XML 3684
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 617-463-9385
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 241441271
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)